{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Randomized Phase II\/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma","item":"https:\/\/www.regionalcancercare.org\/trials\/randomized-phase-ii-iii-study-of-nivolumab-plus-ipilimumab-plus-sargramostim-versus-nivolumab-plus-ipilimumab-in-patients-with-unresectable-stage-iii-or-stage-iv-melanoma\/#breadcrumbitem"}]}